CDAK Insider Trading
Notice: This stock is marked as potentially delisted. It may not be actively trading.
Insider Ownership Percentage: 8.20%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00
Codiak BioSciences Share Price & Price History
Current Price: $0.00
Price Change: +0.30 (1.20%)
As of 09/18/2023 01:00 AM ET
Codiak BioSciences Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/30/2023 | Yalonda Howze | Insider | Sell | 1,628 | $0.20 | $325.60 | 7,458 |  |
| 3/28/2023 | Douglas E Williams | CEO | Sell | 41,667 | $0.18 | $7,500.06 | 7,655 | |
| 1/20/2023 | Konstantin Konstantinov | CTO | Sell | 1,069 | $0.58 | $620.02 | 1,731 | |
| 1/20/2023 | Linda Bain | CFO | Sell | 1,880 | $0.57 | $1,071.60 | 3,120 | |
| 1/20/2023 | Sriram Sathyanarayanan | Insider | Sell | 1,082 | $0.58 | $627.56 | 1,752 | |
Codiak BioSciences Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 2/13/2023 | Forefront Analytics LLC | 99,935 | $40K | 0.0% | +76.9% | 0.271% |  |
| 11/15/2022 | Laurion Capital Management LP | 2,013,300 | $1.57M | 0.0% | +542.6% | 5.466% | |
| 11/15/2022 | Empery Asset Management LP | 237,943 | $0.19M | 1.1% | N/A | 0.646% | |
| 11/15/2022 | Flagship Pioneering Inc. | 3,540,636 | $2.76M | 0.1% | +35.8% | 9.613% | |
| 11/15/2022 | Boxer Capital LLC | 488,157 | $0.38M | 0.0% | -42.6% | 1.325% | |
| 11/14/2022 | Armistice Capital LLC | 1,000,000 | $0.78M | 0.0% | N/A | 2.715% | |
| 11/14/2022 | Ergoteles LLC | 38,019 | $30K | 0.0% | -47.9% | 0.103% | |
| 11/14/2022 | Forefront Analytics LLC | 56,485 | $47K | 0.0% | +208.5% | 0.153% | |
| 11/4/2022 | Prudential Financial Inc. | 36,600 | $29K | 0.0% | N/A | 0.162% | |
| 11/1/2022 | Alaska Permanent Fund Corp | 980,194 | $0.77M | 0.0% | N/A | 4.326% | |
| 8/15/2022 | Laurion Capital Management LP | 313,300 | $0.90M | 0.0% | N/A | 1.382% | |
| 8/12/2022 | Ensign Peak Advisors Inc | 609,105 | $1.75M | 0.0% | -8.9% | 2.688% | |
| 8/1/2022 | Victory Capital Management Inc. | 74,462 | $0.21M | 0.0% | -62.1% | 0.331% | |
| 7/13/2022 | Private Advisor Group LLC | 10,959 | $32K | 0.0% | N/A | 0.049% | |
| 7/13/2022 | Trellus Management Company LLC | 78,527 | $0.23M | 0.3% | -6.6% | 0.349% | |
| 5/11/2022 | GSA Capital Partners LLP | 101,279 | $0.64M | 0.1% | N/A | 0.450% | |
| 5/9/2022 | Forefront Analytics LLC | 19,310 | $0.12M | 0.0% | N/A | 0.086% | |
| 5/4/2022 | Victory Capital Management Inc. | 196,434 | $0.99M | 0.0% | -6.8% | 0.873% | |
| 4/19/2022 | Denali Advisors LLC | 6,500 | $41K | 0.0% | N/A | 0.029% | |
| 2/14/2022 | Boxer Capital LLC | 850,065 | $9.47M | 0.4% | -17.5% | 3.801% | |
| 2/11/2022 | Ensign Peak Advisors Inc | 509,437 | $5.68M | 0.0% | +7.5% | 2.278% | |
| 2/10/2022 | HighTower Advisors LLC | 21,328 | $0.24M | 0.0% | N/A | 0.095% | |
| 2/8/2022 | Northern Trust Corp | 144,189 | $1.61M | 0.0% | +3.0% | 0.645% | |
| 2/7/2022 | Victory Capital Management Inc. | 210,660 | $2.35M | 0.0% | -7.9% | 0.942% | |
| 1/31/2022 | Trellus Management Company LLC | 84,033 | $0.94M | 0.6% | +33.4% | 0.376% | |
| 1/28/2022 | Allspring Global Investments Holdings LLC | 4,258 | $47K | 0.0% | N/A | 0.019% | |
| 11/16/2021 | Metropolitan Life Insurance Co NY | 5,152 | $84K | 0.0% | N/A | 0.023% | |
| 11/15/2021 | Oracle Investment Management Inc. | 700,000 | $11.43M | 1.4% | +3.1% | 3.130% | |
| 11/15/2021 | Ensign Peak Advisors Inc | 474,007 | $7.74M | 0.0% | -27.1% | 2.119% | |
| 11/15/2021 | Franklin Resources Inc. | 333,000 | $5.44M | 0.0% | -50.8% | 1.489% | |
| 11/12/2021 | Geode Capital Management LLC | 229,941 | $3.75M | 0.0% | +11.3% | 1.028% | |
| 11/10/2021 | Citigroup Inc. | 1,815 | $30K | 0.0% | +143.0% | 0.008% | |
| 11/9/2021 | BlackRock Inc. | 926,179 | $15.13M | 0.0% | +4.8% | 4.140% | |
| 11/2/2021 | New York State Common Retirement Fund | 10,949 | $0.18M | 0.0% | -19.2% | 0.049% | |
| 11/2/2021 | Victory Capital Management Inc. | 228,751 | $3.74M | 0.0% | -0.6% | 1.024% | |
| 10/26/2021 | Trellus Management Company LLC | 62,970 | $1.03M | 0.7% | +66.6% | 0.282% | |
Data available starting January 2016
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics S.A.S., Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Read More on Codiak BioSciences
Volume
N/A
Average Volume
1,366,845 shs
Market Capitalization
$58.93 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Beta
3.71
